@article{JTD33563,
author = {Keke Wang and Yanyan Liu and Suiqing Huang and Huayang Li and Jian Hou and Jiaxing Huang and Jiantao Chen and Kangni Feng and Mengya Liang and Guangxian Chen and Zhongkai Wu},
title = {Does an imbalance in circulating vascular endothelial growth factors (VEGFs) cause atrial fibrillation in patients with valvular heart disease?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {12},
year = {2019},
keywords = {},
abstract = {Background: The pathogenesis of atrial fibrillation (AF) remains unclear. Vascular endothelial growth factors (VEGFs) can stimulate fibrosis within the atrium and ventricle. We hypothesized that there is a relationship between the serum VEGFs/soluble vascular endothelial growth factor receptor (sVEGFRs) levels and AF in patients with valvular heart disease (VHD). This provides a new paradigm for studying AF.
Methods: The plasma levels of VEGF-A, VEGF-C, sVEGFR-1 and sVEGFR-2 were detected by enzyme- linked immunosorbent assay (ELISA). A total of 100 people, consisting of AF patients (long-standing, persistent AF; n=49), sinus rhythm (SR) patients (n=31) and healthy controls (n=20), were included in this study.
Results: The plasma levels of VEGF-A were significantly higher in AF patients compared to healthy control (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/33563}
}